Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Risk Assessment generated by a regulatory process
(RA)
published: 31 May 2017
last updated: 22 Feb 2018
Pexa-Vec hepatocellular carcinoma therapy in clinical trial
EN
27 Oct 2015
-
Competent National Authority:Environmental Protection Authority ()Private Bag 63002Wellington,
6140, New ZealandPhone: +64 (0)4 474 5591,Fax: +64 (0)4 914 0433,Email: neworganisms@epa.govt.nz,
-
Pexa-Vec Vaccine| Sillagen | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
- APP202601 Staff assessment report [ English ]
EN
| Record type | Field | Record(s) | |
|---|---|---|---|
| Country's Decision or any other Communication | Risk assessment | 1 | |
